Novel therapeutic approaches in chondrosarcoma.
Loading...
Embargo End Date
ICR Authors
Authors
Polychronidou, G
Karavasilis, V
Pollack, SM
Huang, PH
Lee, A
Jones, RL
Karavasilis, V
Pollack, SM
Huang, PH
Lee, A
Jones, RL
Document Type
Journal Article
Date
2017-03-31
Date Accepted
Abstract
Chondrosarcoma is a malignant tumor of bones, characterized by the production of cartilage matrix. Due to lack of effective treatment for advanced disease, the clinical management of chondrosarcomas is exceptionally challenging. Current research focuses on elucidating the molecular events underlying the pathogenesis of this rare bone malignancy, with the goal of developing new molecularly targeted therapies. Signaling pathways suggested to have a role in chondrosarcoma include Hedgehog, Src, PI3k-Akt-mTOR and angiogenesis. Mutations in IDH1/2, present in more than 50% of primary conventional chondrosarcomas, make the development of IDH inhibitors a promising treatment option. The present review discusses the preclinical and early clinical data on novel targeted therapeutic approaches in chondrosarcoma.
Citation
Future oncology (London, England), 2017, 13 (7), pp. 637 - 648
Source Title
Publisher
FUTURE MEDICINE LTD
ISSN
1479-6694
eISSN
1744-8301
Collections
Research Team
Sarcoma Clinical Trials (R Jones)
Molecular and Systems Oncology
Molecular and Systems Oncology